Ensysce Biosciences, Inc. (ENSC) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2024. Ensysce Biosciences, Inc. is a clinical-stage biotechnology company focused on developing abuse-resistant and overdose-protective opioid therapies. The company's lead product candidate is PF614 (an extended-release TAAP prodrug of oxycodone), which is ready for Phase 3 development, and PF614-MPAR, which is in Phase 1b development. The company has no approved products and has not generated revenue from product sales.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|
| Revenue (Federal Grants) | $181,797 | $487,519 | $1,280,107 |
| Net Loss | $(1,967,793) | $(5,084,356) | $(4,431,108) |
| Net Loss Per Share (Basic/Diluted) | $(0.22) | $(0.67) | $(2.66) |
| Cash and Cash Equivalents | $1,043,231 | $1,043,231 | $3,829,482 |
| Net Cash Used in Operating Activities | N/A | $(5,718,294) | $(6,715,461) |
| Net Cash Provided by Financing Activities | N/A | $5,637,921 | $7,397,241 |
| Total Debt (Notes Payable & Accrued Interest) | $454,463 | $454,463 | $854,697 |
Material Changes vs. Prior Period
- Revenue Decline: Federal grant revenue decreased significantly year-over-year. The MPAR grant funding concluded in December 2023, and the OUD grant revenue was lower in the first half of 2024 compared to 2023 due to the timing of eligible research activities.
- Expense Reduction: Total operating expenses decreased by approximately $1.85 million for the six months ended June 30, 2024, compared to the prior year period. This was primarily driven by a $1.7 million reduction in Research and Development (R&D) expenses due to reduced external costs for clinical and pre-clinical programs.
- Interest Expense Spike: Interest expense for the six months ended June 30, 2024, was $1.28 million, compared to only $1,497 in the same period in 2023. This increase is attributed to the amortization of the original issue discount and debt issuance costs associated with the 2023 Notes.
- Capital Structure: The company executed a 2024 Warrant Inducement in February, raising approximately $4.7 million in gross proceeds. This involved the exercise of existing warrants at a reduced price and the issuance of new warrants. Additionally, the company converted $1.2 million of 2023 Notes into common stock.
Guidance, Outlook, and Risks
- Going Concern: The filing explicitly states that the company's limited revenues and significant operating losses raise substantial doubt about its ability to continue as a going concern for the next 12 months. Management estimates existing cash resources are sufficient to fund operations only into the third quarter of 2024.
- Funding Needs: The company requires substantial additional funding to complete the development and commercialization of its product candidates. Future funding is expected to come from equity offerings, debt financings, or collaborations.
- Grant Outlook: Management expects federal grant funding to increase in the second half of 2024 due to increased preclinical activities under the OUD grant following the selection of a lead drug candidate. Remaining cash funding under grants is approximately $1.9 million, expected to be utilized by August 31, 2024.
- Risks: Key risks include the failure of clinical trials, inability to secure additional financing, potential delisting from Nasdaq, and the uncertainty of commercializing product candidates.
Investor Verification Checklist
- Cash Runway: Verify the company's ability to secure financing before the end of Q3 2024, as current cash ($1.04M) is insufficient for long-term operations.
- Debt Obligations: Review the terms of the remaining 2023 Notes held by a board member ($216k principal) and the forbearance agreement expiring April 2025.
- Grant Dependency: Assess the reliability of the projected increase in NIH/NIDA grant revenue in H2 2024 to offset operating losses.
- Dilution: Monitor the impact of the 2024 Warrant Inducement and the large number of outstanding warrants (over 11 million shares) on future share count and dilution.
- Commitments: Note the approximately $16 million in open purchase orders for research studies, which may require immediate funding to avoid cancellation or penalties.